These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20854749)

  • 21. New and emerging treatments for Alzheimer's disease.
    Corbett A; Ballard C
    Expert Opin Emerg Drugs; 2012 Jun; 17(2):147-56. PubMed ID: 22439621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive deterioration in Alzheimer's disease: is the early course predictive of the later stages?
    Capitani E; Cazzaniga R; Francescani A; Spinnler H
    Neurol Sci; 2004 Oct; 25(4):198-204. PubMed ID: 15549505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?
    Gauthier S; Poirier J
    Alzheimers Dement; 2009 Mar; 5(2):147-8. PubMed ID: 19328447
    [No Abstract]   [Full Text] [Related]  

  • 24. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.
    Blennow K
    Expert Rev Mol Diagn; 2005 Sep; 5(5):661-72. PubMed ID: 16149870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study methods of drugs in Alzheimer disease].
    Dubois B; Stehlé B; Lehner JP; Derouesné C; Bourin M; Lamour Y; Blin O; Jourdain G; Alperovitch A
    Therapie; 1996; 51(4):444-8. PubMed ID: 8953828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease-modifying trials in Alzheimer's disease: a European task force consensus.
    Vellas B; Andrieu S; Sampaio C; Wilcock G;
    Lancet Neurol; 2007 Jan; 6(1):56-62. PubMed ID: 17166802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs in clinical development for Alzheimer's disease: summary and table.
    Drugs Aging; 2012 Jan; 29(1):73-9. PubMed ID: 22191726
    [No Abstract]   [Full Text] [Related]  

  • 31. [Alzheimer's: between hope and despair].
    Nau JY
    Rev Med Suisse; 2010 Sep; 6(262):1740-1. PubMed ID: 21294311
    [No Abstract]   [Full Text] [Related]  

  • 32. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.
    Sabbagh MN; Shill HA
    Curr Opin Investig Drugs; 2010 Jan; 11(1):80-91. PubMed ID: 20047162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The need for thorough phase II studies in medicines development for Alzheimer's disease.
    Gray JA; Fleet D; Winblad B
    Alzheimers Res Ther; 2015 Oct; 7(1):67. PubMed ID: 26503107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
    Cummings J
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding pharmacology in humans: Phase I and Phase II (data generation).
    Merlo Pich E
    Curr Opin Pharmacol; 2011 Oct; 11(5):557-62. PubMed ID: 21783419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Learning from failure.
    Nat Rev Drug Discov; 2010 Jul; 9(7):499. PubMed ID: 20614555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New and different approaches needed for the design and execution of Alzheimer's clinical trials.
    Carrillo MC; Vellas B
    Alzheimers Dement; 2013 Jul; 9(4):436-7. PubMed ID: 23809363
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed.
    Preussler S; Kieser M; Kirchner M
    Biom J; 2019 Mar; 61(2):357-378. PubMed ID: 30182372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed.
    Vellas B
    Lancet Neurol; 2010 Mar; 9(3):235-7. PubMed ID: 20170836
    [No Abstract]   [Full Text] [Related]  

  • 40. Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach.
    Cummings JL
    Dement Geriatr Cogn Disord; 2020; 49(1):22-37. PubMed ID: 32512572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.